Moderna Gives An Update on Its New RNA-based Flu Vaccine

Posted

Massachusetts-based Moderna, best known for its COVID-19 vaccine, is working on more mRNA technology for other diseases. The biotechnology company has over 45 potential treatments, most in clinical trials. This stage in drug development can last for years to a decade. Moderna’s three coronavirus vaccines approved for commercial use are due to enhanced government-subsidized research during the pandemic. 

Moderna’s current focus is on its late-stage flu vaccine, which claims to invoke a higher response against all strains of the influenza virus among all age groups. The study also mentioned that the said vaccine beats the current Sanofi vaccine. Moving forward, Moderna will be on the lookout for other test results to help accelerate its vaccine approval.

Comments

No comments on this item Please log in to comment by clicking here